Research & DevelopmentImmune DisordersConditionsKidney ProblemsGeneral HealthOrgan TransplantsResearch And DevelopmentHealth TechnologyStem Cells
Updated on September 22, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, March 7, 2012 (HealthDay News) -- Researchers report that they were able to create a kind of hybrid immune system in patients who received kidney transplants, a process that appeared to allow the recipients' bodies to accept a foreign organ instead of trying to reject it.
There are caveats. The research is preliminary and only involved a tiny number of patients. Also, the required procedure is expensive and its long-term effects aren't known.
But if it works, the process -- which involves transferring bone marrow cells from the kidney donor to the patient -- could allow organ transplant recipients to avoid a lifetime of taking dozens of pills a day. "It's a huge step forward," said Dr. Suzanne Ildstad, director of the University of Louisville's Institute for Cellular Therapeutics, and co-author of the study published in the March 7 issue of Science Translational Medicine.
The immune system's job is to keep invaders out of the body, but it can do its work too well when a patient needs an organ transplant. "People think that once you get your transplant, everything is simple, but it's really far from that," Ildstad said.
Patients often have to take 15 to 25 pills a day to dampen their immune system, she said, and that can lead to complications such as infections, diabetes, high blood pressure and cancer.
"Even if you're perfect and take your drugs every day, every year there's a certain number of transplants lost to chronic rejection," Ildstad explained.
One way to get the immune system under control is to make it think like the immune system in the person who's donating the organ. That immune system of the donor would recognize the transplanted organ and not try to get rid of it.
In the new procedure, the researchers removed stem cells from the bone marrow of the kidney donors, put them through a special process designed to give them a boost, then inserted them into the organ recipients.
Essentially, the goal is to create a hybrid immune system -- part donor, part recipient -- in the bone marrow of the recipient. The marrow then creates cells in the immune system.
Of eight patients, five have not required any medications to suppress their immune systems, Ildstad said. Two of the patients take the medications at a low dose; one patient experienced complications related to blood poisoning and a blood clot in an artery to the kidneys.
The extra cost per patient beyond the expense of the transplant is about $50,000, Ildstad said. The next step is to determine whether the procedure would work for other kinds of transplants, she said.
Ildstad has a financial interest in Regenerex LLC, a company that participated in the study.
Dr. Tatsuo Kawai, a transplant specialist and associate professor of surgery at Harvard Medical School, said the findings are a "big deal." However, the safety of the procedure still needs to be confirmed, and it remains "highly risky" for the moment, said Kawai, who co-wrote a commentary accompanying the study.
In the commentary, Kawai noted some study weaknesses. Beside its small size, the study lacked a control group of patients who did not receive the new procedure, to allow comparisons. Also, he wrote that it might be difficult for other researchers to validate the findings, as the study doesn't fully disclose manufacturing details of the new process.
For more about organ transplants, visit the U.S. National Library of Medicine.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Read this Next
Other Trending Articles